Specialised Therapeutics welcomes the registration of YORVIPATH by the Therapeutic Goods Administration, “for the treatment of chronic hypoparathyroidism in adults”. YORVIPATH was granted an Orphan Drug Designation and assessed through the TGA’s Priority Review pathway. It is the first and only medicine to be listed on the Australian Register of Therapeutic Goods for the treatment of chronic hypoparathyroidism. YORVIPATH is being made available in Australia by Specialised Therapeutics, under an exclusive distribution agreement with global biopharmaceutical company Ascendis Pharma (ASND) that covers Australia, New Zealand, Singapore, Malaysia, Brunei, Thailand, and Vietnam.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Buy Rating for Ascendis Pharma: Yorvipath’s Strong Market Position and Growth Prospects
- Ascendis Pharma: Favorable Market Position and Strong Prescription Growth Justify Buy Rating
- Ascendis Pharma price target raised to $180 from $175 at Morgan Stanley
- Ascendis Pharma’s Yorvipath: Impressive Launch and Strong Growth Potential Drive Buy Rating
- Potential Share Dilution Looms for Ascendis Pharma: What Investors Need to Know